Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29403746 | 0.99 | EGFR (0.98) | EGFRERBB2MAPTHPGDHTT | |
| Hydrochloric Acid SCHEMBL29403956 | 0.99 | EGFR (0.98) | EGFRERBB2MAPTHPGDHTT | |
| Hydrochloric Acid SCHEMBL25177456 | 0.99 | EGFR (0.98) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL7584861 | 0.90 | EGFR (0.81) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL7578516 | 0.89 | EGFR (0.80) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL7577695 | 0.89 | EGFR (0.80) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL7587008 | 0.89 | EGFR (0.79) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL6994263 | 0.88 | EGFR (0.79) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL6991298 | 0.88 | EGFR (0.79) | EGFRERBB2MAPTHPGDHTT | |
| SCHEMBL6991492 | 0.88 | EGFR (0.78) | EGFRERBB2MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4412717-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH PAN ERBB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118369119-A | Combination therapy of KRAS G12D inhibitors and pan ErbB family inhibitors | 米拉蒂治疗股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2023059596-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2020132459-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-2373329-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | The Regents of the University of California (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-29 | — | — | US | disclosed |
| WO-2010123527-A2 | USE OF EPIDERMAL GROWTH FACTOR INHIBITORS IN THE TREATMENT OF VIRAL INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110236349-A1 | Use of Epidermal Growth Factor Inhibitors in the Treatment of Viral Infection | EGFR, HDGF, HGF | EGFR 1/4885ERBB2 11/4885MAPT 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.